Trials / Conditions / Hemophilia A With Inhibitors

Hemophilia A With Inhibitors

9 registered clinical trials studyying Hemophilia A With Inhibitors.

Status	Trial	Sponsor	Phase
Completed	A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participa NCT03093480	Bioverativ, a Sanofi company	Phase 4
Withdrawn	Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography NCT03002480	Children's Hospital Los Angeles	N/A
Completed	A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa NCT02448680	Laboratoire français de Fractionnement et de Biotechnologies	Phase 3
Terminated	Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episode NCT02484638	CSL Behring	Phase 2 / Phase 3
Completed	Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors NCT02020369	rEVO Biologics	Phase 3
Unknown	rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors NCT01105546	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	Phase 2
Completed	Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors NCT00221195	Tulane University School of Medicine	Phase 2 / Phase 3
Completed	The Malmö International Brother Study (MIBS) NCT00231751	Skane University Hospital	—
Terminated	International Immune Tolerance Study NCT00212472	New York Presbyterian Hospital	N/A